Table 2 Parabacteroides and other diseases
From: Parabacteroides as a promising target for disease intervention: current stage and pending issues
Year | Bacterial species | Diseases | Outcomes | REF. |
|---|---|---|---|---|
2023 | P. distasonis | Cadmium exposure | P. distasonis was capable of restoring the intestinal damage caused by Cd exposure and reducing the Cd content in essential organs, blood, and feces to varying degrees. Moreover, its metabolite succinic acid plays a crucial role in promoting Cd excretion in Cd-exposed mice. | |
2023 | P. distasonis | Hepatocyte pyroptosis | P. distasonis can reduce taurochenodesoxycholic acid (TCDCA) levels by enhancing BSH activity and inhibiting ileal FXR. The reduction of TCDCA improved the activation of hepatic stellate cells (HSCs) by decreasing the mitochondrial permeability transition (MPT)-Caspase-11 pyroptosis pathway. | |
2023 | P. distasonis | Non-alcoholic steatohepatitis | P. distasonis uses inulin to produce the odd-chain fatty acid pentadecanoic acid, which alleviates non-alcoholic steatohepatitis via improved barrier function in mice. | |
2023 | P. merdae | Sepsis | P. merdae can protect septic mice by ameliorating the inflammatory response. | |
2024 | P. distasonis | Experimental autoimmune encephalomyelitis | P. distasonis can increase the frequency of regulatory T cells, induce an anti-inflammatory milieu in mesenteric lymph nodes, and reduce the activation of T cells at the priming site. | |
2024 | P. distasonis | Chronic abdominal pain | P. distasonis is capable of alleviating chronic abdominal pain by reducing the activation signal of neuronal cells stimulated by bradykinin and the activation level of nociceptors. | |
2024 | P. distasonis | Organ transplantation | Oral administration of P. distasonis to mice harboring a diverse microbiota significantly prolonged skin allograft survival. | |
2024 | P. goldsteinii | Acute kidney injury | Administration of P. goldsteinii showed protective effects against acute kidney injury by ameliorating perturbations in BUN, Scr, and cystatin C levels, as well as attenuating the pathological changes in kidneys. | |
2024 | P. distasonis | Acute ischemic stroke with hyperuricemia | P. distasonis can increase beneficial commensal bacteria, significantly improve neurological deficits, and reduce the level of serum uric acid in HAS rats, as well as reduce pathological damages and BBB disruption. | |
2024 | P. goldsteinii | Psoriasis | P. goldsteinii-derived OMVs can improve systemic immune homeostasis and relieve the symptoms of psoriasis by regulating the IL-23/Th17 axis positive feedback loop. |
